Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro

Journal of Endocrinological Investigation

Volumn 26, Issue 8, 2003, Pages 743-747

  Orkin, R D ^a   New, D I ^a   Norman, D ^a   Chew, S L ^a   Clark, A J L ^a   Grossman, A B ^a   Korbonits, Márta ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Calcium; Desensitisation; GH secretagogues; Ghrelin; Ghrelin receptor; GHS; GHS receptor; Hexarelin

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; COMPLEMENTARY DNA; FURA 2; GHRELIN; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE DERIVATIVE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1A; HEXARELIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APPETITE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CELL STIMULATION; CHINESE HAMSTER; CHO CELL; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; FEMALE; FLUORESCENCE ANALYSIS; GENETIC CODE; GENETIC TRANSFECTION; HORMONAL REGULATION; IN VITRO STUDY; NONHUMAN; OVARY CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0344013162     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347357     Document Type: Article

References (33)

1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
2. Collins S, CAron MG, Lefkowitz RJ. From ligand binding to gene expression: New insights into the regulation of G-protein-coupled receptors. Trends Biochem Sci 1992, 17: 37-9.
3. Badger TM, Millard WJ, McMormick GF, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984, 115: 1432-8.
4. Cheng J, Wu TJ, Butler B, Cheng K. Growth hormone releasing peptides: A comparison of the growth hormone releasing peptides: A comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci 1997; 60: 1385-92.
5. Yoshihara F, Kojima M, Hosoda H, Nakazato M, Kangawa K. Ghrelin: A novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metab Care 2002, 5: 391-5.
6. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites. J Endocrinol 1991, 129: 11-9.
7. Klinger B, Sibergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996, 134: 716-9.
8. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998; 83: 1644-9.
9. Rahim A, Shalet SM. Does desensitisation to growth hormone secretagogues occur? In: Dieguez C, Ghigo E, Boghen MF, Casanueva FF eds. Growth Hormone Secretagogues: Basic Findings and Clinical Implications. Rotterdam: Elsevier 1999, 175-81.
10. Freir S, Weiss O, Eran M, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999, 44: 704-8.
11. Bohm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 1997, 322: 1-18.
12. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res 1996, 51: 319-51.
13. Korbonits M, Jacobs RA, Aylwin SBJ, et al. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab 1998, 83: 3624-30.
14. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260: 3440-50.
15. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974-7.
16. Cheng K, Chan WW, Butler B, Barreto Jr. A, Smith RG. Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-D-Phe-Lys-NH2-induced growth hormone release from rat primary pituitary cells. Endocrinology 1991, 129: 3337-42.
17. Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by 2 mechanisms. Endocrinology 1994, 135: 1100-8.
18. Dickson SL, Leng G, Dyball REJ, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinol 1995; 61: 36-43.
19. Smith RG, Van Der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Rev 1997, 18: 621-45.
20. Pong SS, Chaung L-YP, Dean CD, et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996, 10: 57-61.
21. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic heptapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114: 1537-45.
22. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027-35.
23. 4), insulin and IGF-1 levels in beagles. Proc of the 77th Annual Meet of the Endocrine Soc 1994, 660: (abstract)
24. Laron Z, Frenkel J, Deghenghi R, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 1995, 43: 631-5.
25. Mericq V, Cassorla F, Salazar T, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998, 83: 2355-60.
26. Fairhall KM, Mynett A, Smith RG, Robinson ICAF. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the nonpeptide GH secretagogue, L-692,585. J Endocrinol 1995, 145: 417-26.
27. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: Partial response attenuation. J Clin Endocrinol Metab 191, 72, 1312-6.
28. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993, 76: 1202-8.
29. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993, 77: 1641-7.
30. Nijland EA, Strasburger CJ, PoppSnijders C, VanderWal PS, Van Der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur J Endocrinol 1998, 139: 395-401.
31. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86: 1116-25.
32. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002, 87: 2988.
33. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649-61.